These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The growth and spontaneous dissemination of melanoma B16 and Lewis lung tumour in two sub-strains of C57BL/6J mice treated with Corynebacterium parvum and/or levamisole. Boeryd B; Benktson A Clin Exp Metastasis; 1983; 1(3):289-95. PubMed ID: 6546203 [TBL] [Abstract][Full Text] [Related]
25. Depression of hepatic biotransformations by chemical immunoadjuvants. Giampietri A; Puccetti P; Contessa AR J Immunopharmacol; 1981; 3(2):251-64. PubMed ID: 7338632 [TBL] [Abstract][Full Text] [Related]
26. Combined radiotherapy, chemotherapy, and maltose tetrapalmitate immunotherapy in the treatment of 4'dimethylaminoazobenzene-induced liver cancer. Nigam VN; Brière N; Bonaventure J; Pageau R; Bissonnette E; Brailovsky C; Madarnas P Anticancer Res; 1986; 6(2):245-50. PubMed ID: 3085575 [TBL] [Abstract][Full Text] [Related]
27. Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants. Mathe G Comp Immunol Microbiol Infect Dis; 1980; 3(4):407-32. PubMed ID: 6451350 [No Abstract] [Full Text] [Related]
28. Host responses in adjuvant contact suppression of experimental rat tumours. Pimm MV; Hopper DG; Baldwin RW Dev Biol Stand; 1977 Apr 13-15; 38():349-54. PubMed ID: 344098 [TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacies of maltose tetrapalmitate immunotherapy alone and in combinations with radiotherapy and with cyclophosphamide chemotherapy against dimethylhydrazine induced colon and anal cancers in CDI mice. Benrezzak O; Madarnas P; Pageau R; Nigam VN Anticancer Res; 1988; 8(3):499-506. PubMed ID: 3389753 [TBL] [Abstract][Full Text] [Related]
30. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Hrouda D; Souberbielle BE; Kayaga J; Corbishley CM; Kirby RS; Dalgleish AG Br J Urol; 1998 Dec; 82(6):870-6. PubMed ID: 9883227 [TBL] [Abstract][Full Text] [Related]
31. Induction of antitumor immunity employing live tumor cells and maltose tetrapalmitate. Bonaventure J; Nigam VN; Brailovsky CA J Biol Response Mod; 1985 Jun; 4(3):258-63. PubMed ID: 4020385 [TBL] [Abstract][Full Text] [Related]
32. Maltose tetrapalmitate, a nontoxic immunopotentiator with antitumor activity. Nigam VN; Brailovsky CA; Chopra C Cancer Res; 1978 Oct; 38(10):3315-21. PubMed ID: 688221 [TBL] [Abstract][Full Text] [Related]
33. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856 [TBL] [Abstract][Full Text] [Related]
34. Effect of immunomodulators on effector cells involved in antibody-dependent cellular cytotoxicity: Brief communication. Tagliabue A; Mantovani A; Polentarutti N; Vecchi A; Spreafico F J Natl Cancer Inst; 1977 Sep; 59(3):1019-22. PubMed ID: 894742 [TBL] [Abstract][Full Text] [Related]
35. Abrogation of antitumor effects of Corynebacterium parvum and BCG by antimacrophage agents: brief communication. Keller R J Natl Cancer Inst; 1977 Dec; 59(6):1751-3. PubMed ID: 200763 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the effect of viral paramunity inducers PIND-AVI and PIND-ORF with that of BCG, Corynebacterium parvum and levamisole on the growth of radiation-induced murine osteosarcoma. Müller-Brunecker G; Erfle V; Mayr A Zentralbl Veterinarmed B; 1986 Apr; 33(3):188-95. PubMed ID: 3463079 [No Abstract] [Full Text] [Related]
37. The influence of nonspecific immunotherapy on the course of murine melanoma. Woods JE; Ritts RE J Surg Oncol; 1977; 9(1):15-20. PubMed ID: 839793 [TBL] [Abstract][Full Text] [Related]
38. Effect of maltose tetrapalmitate on tumor vascularization and tumor growth. Benrezzak O; Bissonnette E; Madarnas P; Nigam VN Anticancer Res; 1989; 9(6):1815-8. PubMed ID: 2483306 [TBL] [Abstract][Full Text] [Related]
39. [Tumor ablation with focalized ultrasound. In vivo experiment with prostatic adenocarcinoma R3327 Mat-Ly-Lu]. Margonari J; Chapelon JY; Gelet A; Cathignol D; Bouvier R; Gorry F Prog Urol; 1992 Apr; 2(2):207-19. PubMed ID: 1302056 [TBL] [Abstract][Full Text] [Related]